Skip to main content

Table 1 Baseline characteristics of children patients with SDNS and SRNS

From: Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital

Characteristics Ntotal SDNS (n) SRNS (n) P value
Gender 48 26 22 0.529
 Male 26 (54.2%) 13 (50.0%) 13 (59.1%)
 Female 22 (45.8%) 13 (50.0%) 9 (40.9%)
Age at onset of treatment (yr) 48 (9.17 ± 2.30) 26 (9.42 ± 0.21) 22 (7.64 ± 0.32) 0.126
Proteinuria before RTX treatment   0.049
 Nephrotic 24 (50.0%) 9 (34.6%) 15 (68.2%)
 Sub-nephrotic 18 (37.5%) 12 (46.2%) 6 (27.3%)
 Physiologic 6 (12.5%) 5 (19.2%) 1 (4.5%)
Renal pathologya   0.016
 MCNS 5 (10.4%) 4 (15.4%) 1 (4.5%)
 FSGS 15 (31.2%) 4 (15.4%) 11 (50.0%)
 DMP 27 (56.2%) 18 (69.2%) 9 (41.0%)
 MGN 1 (2.1%) 0 (0.0%) 1 (4.5%)
Concomitant treatmentsb   0.302
 Steroid 4 (8.3%) 1 (3.8%) 3 (13.7%)
 CNI 11 (22.9%) 6 (23.1%) 5 (22.7%)
 MMF 19 (39.6%) 13 (50.0%) 6 (27.3%)
 CNI plus MMF 14 (29.2%) 6 (23.1%) 8 (36.3%)
Early outcome (6 months after RTX)   0.005
 Complete remission 23 (47.9%) 18 (69.2%) 5 (22.7%)
 Partial remission 12 (25.0%) 3 (11.6%) 9 (41.0%)
 No response 13 (27.1%) 5 (19.2%) 8 (36.3%)
Outcome at last follow-up   0.101
 Complete remission 18 (37.5%) 13 (50.0%) 5 (22.7%)
 Partial remission 18 (37.5%) 9 (34.6%) 9 (41.0%)
 No response 12 (25.0%) 4 (15.4%) 8 (36.3%)
Existence of complication   0.196
 Yes 15 (31.2%) 10 (38.5%) 5 (22.7%)
 No 33 (68.8%) 16 (61.5%) 17 (77.3%)
Disease duration (month)c 48 (54.54 ± 37.12) 26 (67.12 ± 39.95) 22 (39.68 ± 34.27) 0.015
Therapeutic response onset (month)d 48 (1.55 ± 1.86) 26 (1.27 ± 1.61) 22 (1.88 ± 2.82) 0.372
The first relapse time (month) 35 (3.88 ± 4.51) 21 (4.10 ± 5.47) 14 (3.57 ± 7.12) 0.807
  1. aMCNS Minimal change nephrotic syndrome, FSGS Focal and segmental glomerulosclerosis, DMP Diffuse mesangial proliferation, MGN Membranous glomerulonephritis
  2. bCNI Calcineurin inhibitor, MMF Mycophenolate mofetil
  3. cFrom diagnosis to administration
  4. d After the first injection of RTX